Mayne Banks On Nextstellis As Generics Business Suffers
Company Sees 6% Decline In Revenues But Dermatology Portfolio Continues To Grow
Executive Summary
Mayne Pharma has expressed confidence after its recent US launch of Nextstellis (estetrol/drospirenone) 14.2mg/3mg oral contraceptive tablets. While the firm’s overall sales dipped by 6% in its financial first half, Mayne expects its recent and near-term launches, particularly key dermatology products, to help reverse the trend.
You may also be interested in...
Gloomy First Half Results For Mayne
Revenue falls 33% over the half year for the ailing Australian pharmaceutical as it pivots from generics to the branded market
Dr Reddy’s Swallows Up Mayne’s US Generics Portfolio For $90m+
Dr Reddy’s has struck a deal to pay at least $90m for the US prescription generics portfolio of Mayne Pharma. The transaction covers products including Mayne’s recently-launched rival to NuvaRing.
Mayne And Mithra Add Further US NuvaRing Rival
Mayne Pharma and partner Mithra have announced the launch of their Haloette generic version of NuvaRing in the US, adding further competition to a field that already includes Amneal and Teva as well as Prasco’s authorized generic.